ALIM - アリメラ・サイエンシ―ズ （Alimera Sciences Inc.）

Data was included in scientific programming at the annual meeting of The Retina Society ATLANTA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announces findings from a recent meeting

Alimera Sciences, Inc. (NASDAQ:NASDAQ:ALIM) Q3 2022 Results Conference Call November 14, 2022 09:00 AM ET Company Participants Scott Gordon - CORE, Investor Relations Rick Eiswirth -…

ALPHARETTA, Ga. (AP) _ Alimera Sciences Inc. (ALIM) on Monday reported a loss of $5.3 million in its third quarter. On a per-share basis, the Alpharetta, Georgia-based company said it had a loss of 75 cents. The eye drug developer posted revenue of $13.6 million in the period. The …

Alimera Sciences press release (ALIM): Q3 GAAP EPS of -$0.75 misses by $0.35.Revenue of $13.6M (+11.9% Y/Y) misses by $1.45M.On September 30, 2022, Alimera had cash and cash…

Consolidated Net Product Revenue of $13.6 Million, up 11% vs. Third Quarter of 2021 Net Product Revenue Was Unfavorably Impacted by Approximately $800,000 in Foreign Currency Fluctuations Excludin…

Positive findings from the RIVER study and data on retreatment with ILUVIEN available ATLANTA, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that clinical data for ILUVIEN

Reimbursement granted with no restrictions to the label Alimera to begin selling later in Q3 ATLANTA, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that Alimera Sciences

Alimera Sciences, Inc. (NASDAQ:NASDAQ:ALIM) Q2 2022 Earnings Conference Call July 27, 2022 09:00 AM ET Company Participants Scott Gordon - CORE, Investor Relations Rick Eiswirth - President…

Alimera Sciences (NASDAQ: ALIM ) reported its Q2 earnings results on Wednesday, July 27, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Alimera Sciences beat estimated earnings by 18.18%, reporting an EPS of $-0.45 versus … Full story available on Benzinga.com

ATLANTA, July 27, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announced financial results for the second quarter of 2022. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.

Alimera Sciences, Inc. (NASDAQ:NASDAQ:ALIM) Q2 2022 Earnings Conference Call July 27, 2022 09:00 AM ET Company Participants Scott Gordon - CORE, Investor Relations Rick Eiswirth - President…

Alimera Sciences (NASDAQ: ALIM ) reported its Q2 earnings results on Wednesday, July 27, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Alimera Sciences beat estimated earnings by 18.18%, reporting an EPS of $-0.45 versus … Full story available on Benzinga.com

ATLANTA, July 27, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announced financial results for the second quarter of 2022. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.

Alimera Sciences (NASDAQ:ALIM): Q2

Alimera Sciences (ALIM) is scheduled to announce Q2 earnings results on Wednesday, July 27th, before market open.The consensus EPS Estimate is -$0.53 and the consensus Revenue Estimate is…